Galderma (GLDM) Faces FDA Setback for Botox Rival Drug

Galderma's stock dropped following the FDA's second setback regarding its rival to Botox. The company has been working on a new injectable treatment aiming to compete in the aesthetics market. The setbacks from the FDA could delay the product launch, impacting anticipated revenue streams. This event raises concerns about regulatory hurdles and market positioning for Galderma (GLDM).